The capital will support ongoing clinical trials in multiple locations and advance development for Lung Therapeutics’ “transformative” drug for fibrosis, LTI-03.
The company has now raised $17 million in outside funding, aside from the $27 million awarded for discovery research and development.
The latest raise was headed by Bios Partners, a life sciences private equity firm out of Dallas and Fort Worth, Texas.
More articles on supply chain:
Mylan keeps EpiPen costs high despite intense public scrutiny
6 FDA decisions to keep an eye on in June
C-suites containing supply chain leaders have better operational performance: 7 survey insights
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.